Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

Also called NCT07405216

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Centenario Hospital Miguel Hidalgo (from the registry)
Registry
  • NCT NCT07405216
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07405216. Randomized; triple masking; primary purpose treatment. Start 2026-04-23 (actual); primary completion 2027-05-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Acronym
IECA-MEX
Condition
Chronic Kidney Disease (Mild to Moderate)
Condition
Albuminuria
Condition
Adolescent
Condition
Sodium Glucose Co-Transporter 2 Inhibitors
Intervention (Drug)
Dapagliflozin (10mg Tab)
Intervention (Drug)
Placebo
Lead sponsor
Centenario Hospital Miguel Hidalgo (class: other)

Record details

Record id
cardio:ct-nct07405216
Content hash
f1a15769bc30c9c109a6538b40011f8da14aa4fa0505efcff6d5feb39c1d894c